Revati Patil, Pradip Devhare, Ajay Srinivasan, Dadasaheb Akolkar*, Darshana Patil, Vineet Datta, Ashwini Ghaisas, Chirantan Bose, Shankar Somashekar, Jinumary John, Sanket Patil, Sachin Apurwa, Navin Srivastava and Rajan Datar
Datar Cancer Genetics Limited, Nasik, India
*Corresponding Author: Dadasaheb Akolkar, Research and Innovation Department, Datar Cancer Genetics Limited, Nasik, India.
Received: July 21, 2020; Published: September 25, 2020
Pilomatrical carcinoma is an exceedingly rare, locally aggressive malignancy of the hair follicle. It may arise de novo as a solitary lesion or through malignant transformation from its pre-existing benign counterpart, pilomatrixoma. There are no standard treatment guidelines and wide surgical excision of the primary lesion followed by adjuvant radiotherapy remains principal treatment modality. However, high recurrence rate after primary treatment, presence of nodal and systemic metastases which is non-responsive to chemotherapy are major concerns in disease management. Here, we report a case of a 45-year-old female with recurrent pilomatrical carcinoma who opted for personalized treatment guidance based on Encyclopedic Tumor Analysis (ETA). Molecular analysis of tumor tissue identified a novel EIF3E-RSPO2 gene rearrangement, SETD2 mutation and overexpression of VEGFA and RET genes. These molecular alterations along with synchronous chemo-sensitivity assay on tumor derived cells helped in defining combinatorial off label therapy regimens which countered disease progression at each instance and led to the durable regression of primary as well as metastatic lesions. This personalized treatment management strategy described herein effectively addressed advanced, refractory disease for which current Standard of Care (SoC) options were unviable.
Keywords: Merkel Cell Carcinoma (MCC); CD56; CK20; CK7; Synaptophysin
Citation: Dadasaheb Akolkar., et al. “Management of a Refractory EIF3E-RSPO2 Fusion Positive Pilomatrical Cancer Patient with Encyclopedic Tumor Analysis Guided Treatment". Acta Scientific Cancer Biology 4.10 (2020): 19-23.
Copyright: © 2020 Dadasaheb Akolkar., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.